Lumeran, Jerald Kurt D.

HRN: 21-74-74  Sex: Male

Patient Encounter


Audit Details

Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
04/15/2024
CLINDAMYCIN 150MG/ML, 4ML (AMP)
04/15/2024
04/22/2024
IV
150mg
Q6
Cellulitis
Waiting Final Action 

Indication:  Empiric    Type of Infection:  Skin & Soft TissueProphylaxis    Compliance to guidelines: Compliant To Guidelines

Initial appropriateness: Yes   

Final appropriateness: Yes   

Overall appropriateness: Yes 

Intervention



Type of Intervention done:

                    

           


Acceptance: